Navigation Links
Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
Date:5/27/2008

First Phase III study performed solely in high risk node-negative population to show significant improvement in Disease Free Survival (DFS)

BRIDGEWATER, N.J., May 27 /PRNewswire-FirstCall/ -- Sanofi-aventis and GEICAM (Grupo Espanol de Investigacion en Cancer de Mama) announced today that for women with high-risk node-negative early stage breast cancer adjuvant treatment (post surgery) with Taxotere(R) (docetaxel) Injection Concentrate as part of the TAC regimen (Taxotere(R), doxorubicin, cyclophosphamide) was associated with a significant improvement in Disease Free Survival (DFS) compared to a standard FAC regimen (5-Fluorouracil, doxorubicin, cyclophosphamide) in the GEICAM 9805/Target-0 study.

The results will be presented at the 2008 annual meeting of the American Society of Clinical Oncology, ASCO, in Chicago (Monday June 2, 2008, 2-6 pm, poster number 1D, abstract 542).

In Europe and North America, most breast cancer patients are diagnosed at an early stage, before the tumor has spread to the lymph nodes. However, few clinical trials in the past were dedicated exclusively to this population of patients. GEICAM 9805/Target-0 is the first taxane-based study to exclusively enroll women with node-negative early stage breast cancer considered to be at high risk for recurrence. High risk patients were defined as having at least one of the following St Gallen 1998 criteria: patient's age <35 years, tumor histological grade II/III, tumor size >2 cm, or hormone-receptor (estrogen and/or progesterone receptor) negative tumor.

The 1059 women enrolled in this multicenter, phase III study were randomized to receive either TAC (n=539) or FAC (n=520) after surgical resection of their tumor. Therapy was given every three weeks for a total of 6 cycles. The primary end point was Disease Free Survival (DFS) and secondary end points included overall survival (OS), safety, and quality of life.

Analysis of efficacy, determined by DFS, wa
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
2. Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
3. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
4. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
5. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
6. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
7. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
8. Gene Therapy Provides Vision to People who Were Nearly Blind
9. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
10. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
11. Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Corporation (NASDAQ: HSKA ), a provider of ... today announced that Robert Grieve, Heska,s Chairman and CEO, will ... (PT), on March 14, 2012, Salon 1, Burgandy Track.  The ... Carlton, 1 Ritz Carlton Drive, Dana Point, California.  Dr. Grieve ...
... BETHESDA, Md., Feb. 23, 2012  Northwest Biotherapeutics (OTC.BB: NWBO) ... clinical trial sites open and recruiting across the United ... DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most ... milestone ahead of schedule, as the Company had projected ...
Cached Medicine Technology:Heska to Present at the 24th Annual ROTH Conference 2NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection 2NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection 3
(Date:4/18/2014)... new medical-testing device is being prepped to enter ... improve diagnosis of certain diseases in remote areas, ... series of investigations aboard the International Space Station ... the space-tested concept of capillary flow to diagnose ... David Kelso, Ph.D., a researcher at Northwestern University ...
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... Weight loss improves the sexual health of obese men with ... placed 31 obese men with type 2 diabetes on either ... diet meant to decrease calorie intake by 600 calories a ... to an easing of erectile dysfunction and improved sexual desire ...
... People living in a region of the southeastern United States ... higher rates of stroke deaths than the rest of the ... risk for sepsis, a severe illness in which bacteria overwhelms ... sepsis across the United States," said Dr. Henry Wang, associate ...
... University of Massachusetts Medical School have uncovered a novel ... immune response for malaria. Activation of this pathway appears ... by the immune system that may contribute to inflammation ... part in susceptibility for the most common and lethal ...
... , THURSDAY, Aug. 4 (HealthDay News) -- A ... comfortable using the clot-busting drug tissue plasminogen activator (tPA) to ... finds. An ischemic stroke is caused by blocked blood ... of neurology residents who say they,re comfortable using tPA rose ...
... have completed a comprehensive map of genetic mutations occurring ... The findings, reported in the Aug. 4 issue ... biological cause of the tumors, they say. To ... seven oligodendroglioma tissue samples, and focused attention on recurring ...
... the United States spend nearly four times as much dealing ... Most of the difference stems from the fact that Canadian ... multiple payers in the United States. These findings are ... -- the result of a research collaboration among Weill Cornell ...
Cached Medicine News:Health News:U.S. 'Stroke Belt' May Also Be 'Sepsis Belt' 2Health News:Targeting innate immunity in malaria 2Health News:Targeting innate immunity in malaria 3Health News:More Neurology Residents Using Clot-Busting Drug for Stroke 2Health News:Johns Hopkins scientists map genes for common form of brain cancer 2Health News:Johns Hopkins scientists map genes for common form of brain cancer 3Health News:US physician practices spend 4 times Canadian practices 2Health News:US physician practices spend 4 times Canadian practices 3
Cholesterol/HDL with 200 tests....
Intended for the in vitro precipitation of very low density and low density lipoproteins in serum or plasma. Single vial, dry powder precipitating reagent. Total cholesterol reagent not included....
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
... the quantitative determination of ... vials, dry powder reagents. ... NADPH to eliminate interferences ... Reaction: Enzymatic, endpoint. Wavelength: ...
Medicine Products: